NRX Pharmaceuticals Inc Stock
NRX Pharmaceuticals Inc Stock price
Key metrics
| Market capitalization | $38.74m |
| Enterprise Value | $43.76m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | negative |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-20.48m |
| Free Cash Flow (TTM) Free Cash Flow | $-12.36m |
| Cash position | $1.65m |
Is NRX Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
NRX Pharmaceuticals Inc Stock Analysis
Analyst Opinions
3 Analysts have issued a NRX Pharmaceuticals Inc forecast:
Analyst Opinions
3 Analysts have issued a NRX Pharmaceuticals Inc forecast:
Financial data from NRX Pharmaceuticals Inc
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.01 -0.01 |
0%
0%
|
|
| EBITDA | -20 -20 |
38%
38%
|
EBIT (Operating Income) EBIT | -20 -20 |
38%
38%
|
| Net Profit | -20 -20 |
43%
43%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about NRX Pharmaceuticals Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
NRX Pharmaceuticals Inc Stock News
Company Profile
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.
| Head office | United States |
| CEO | Jonathan Javitt |
| Founded | 2017 |
| Website | www.nrxpharma.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
